Mudduluru Giridhar, Medved Fabian, Grobholz Rainer, Jost Camela, Gruber Anette, Leupold Joerg H, Post Stefan, Jansen Aaron, Colburn Nancy H, Allgayer Heike
Department of Experimental Surgery Mannheim/Molecular Oncology of Solid Tumors, Deutsches Krebsforschungszentrum and University Heidelberg, Mannheim, Germany.
Cancer. 2007 Oct 15;110(8):1697-707. doi: 10.1002/cncr.22983.
Programmed cell death 4 (Pdcd4) inhibits malignant transformation, and initial studies of Pdcd4 suggested the regulation of Pdcd4 localization by protein kinase B (Akt). However, supporting patient tissue data are missing, and the diagnostic/prognostic potential of Pdcd4 rarely has been studied. The objectives of the current were 1) to determine Pdcd4 as a diagnostic marker in the adenoma-carcinoma sequence, 2) to support phosphorylated Akt (pAkt)-mediated Pdcd4 regulation in vivo, and 3) to obtain the first prognostic evidence of Pdcd4 in colorectal cancer.
Tumor samples and normal tissues from 71 patients with colorectal cancer who were followed prospectively (median follow-up, 36 months) and 42 adenomas were analyzed for Pdcd4, Akt, and pAkt in immunohistochemical and Western blot analyses.
A significant reduction in Pdcd4 was observed between normal mucosa and adenomas and between adenomas and tumor samples (P < .01 and P < .01, respectively). Normal mucosa demonstrated strong nuclear Pdcd4, which was reduced significantly in adenomas (P < .01) and almost was lost in tumors (P < .01). pAkt was correlated inversely with Pdcd4 and with the transition of Pdcd4 from nucleus to cytoplasm (P < .01). Kaplan-Meier analysis (using the Mantel-Cox log-rank test) indicated a significant correlation between the loss of total and nuclear Pdcd4 in tumors and overall survival (P < .05 and P < .02, respectively) and disease-specific survival (P < .01 and P < .01, respectively). In multivariate analysis, loss of total or nuclear Pdcd4 was an independent predictor of disease-specific or overall survival.
To the authors' knowledge, this is the first study to demonstrate an independent prognostic impact of Pdcd4 and its expression pattern in colorectal cancer. Data from this study support the regulation of Pdcd4 localization by pAkt in vivo. Pdcd4 immunohistochemistry may be useful as a supportive diagnostic tool for the transition between normal, adenoma, and tumor tissues.
程序性细胞死亡4(Pdcd4)可抑制恶性转化,对Pdcd4的初步研究表明蛋白激酶B(Akt)可调节Pdcd4的定位。然而,目前尚缺乏支持性的患者组织数据,且Pdcd4的诊断/预后潜力鲜有研究。本研究的目的是:1)确定Pdcd4作为腺瘤-癌序列中的诊断标志物;2)支持体内磷酸化Akt(pAkt)介导的Pdcd4调节;3)获得Pdcd4在结直肠癌中的首个预后证据。
对71例接受前瞻性随访(中位随访时间36个月)的结直肠癌患者的肿瘤样本和正常组织以及42例腺瘤进行免疫组织化学和蛋白质印迹分析,检测Pdcd4、Akt和pAkt。
在正常黏膜与腺瘤之间以及腺瘤与肿瘤样本之间观察到Pdcd4显著降低(分别为P <.01和P <.01)。正常黏膜显示强核Pdcd4,在腺瘤中显著降低(P <.01),在肿瘤中几乎消失(P <.01)。pAkt与Pdcd4以及Pdcd4从细胞核向细胞质的转变呈负相关(P <.01)。Kaplan-Meier分析(使用Mantel-Cox对数秩检验)表明,肿瘤中总Pdcd4和核Pdcd4的缺失与总生存期(分别为P <.05和P <.02)以及疾病特异性生存期(分别为P <.01和P <.01)显著相关。在多变量分析中,总Pdcd4或核Pdcd4的缺失是疾病特异性生存期或总生存期的独立预测因素。
据作者所知,这是第一项证明Pdcd4及其表达模式在结直肠癌中具有独立预后影响的研究。本研究数据支持体内pAkt对Pdcd4定位的调节。Pdcd4免疫组织化学可能作为正常、腺瘤和肿瘤组织之间转变的辅助诊断工具。